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Abstract 
 
Introduction  
We evaluated the efficacy of various strategies utilized for the control of postoperative pain after 
minimally invasive hysterectomy.  The primary enhanced recovery after surgery (ERAS) 
protocol of interest utilized premedication (acetaminophen, celecoxib and pregabalin), then 
intraoperative subcutaneous liposomal bupivacaine followed by scheduled oral acetaminophen 
and ibuprofen postoperatively.  Patients also had tramadol and oxycodone as needed for 
moderate or severe breakthrough pain, respectively.   
 
Materials and Methods 
 
We conducted a retrospective cohort study that included all patients who underwent minimally 
invasive hysterectomy (total laparoscopic hysterectomy and laparoscopic-assisted vaginal 
hysterectomy) for both benign and oncologic indications over a two-year period.  We then 
compared six protocols; three were ERAS protocols and three were traditional pain control 
methods.  The control group was comprised of the traditional pain control group without 
intraoperative placement of local analgesia.   Patient medical records were evaluated for 
demographics, surgical characteristics, opioid type and dose, pain scores, length of stay and 
complications.  Opioids were converted to oral morphine dose equivalents. 
 
Results 
 
954 patients were included within the six protocols.  Median opioid usage was the lowest in the 
ERAS group with premedication and highest in the control group (22.5mg versus 55.0mg, 
p<0.001).  Patients in the ERAS group with premedication, when compared to control, were 
three times more likely to decline opioids, (p<0.001) without any concomitant increase in pain 
scores. 
 
Discussion  
 
ERAS protocol with premedication was associated with significant reductions in postoperative 
opioid use and median pain scores when compared to traditional methods. 
 
Keywords 
 
Enhanced Recovery after Surgery, ERAS, Multimodal, Opioids, Pain Control, Substance Abuse 
 
Introduction 
 
Enhanced recovery after surgery (ERAS) programs have been shown to reduce hospital stay and 
decrease cost, opioid use and postoperative complications without any impact on patient pain 
control and satisfaction scores.1-7 ERAS programs vary in their specific respective regimens. 
Generally they include premedication, early ambulation, early urinary catheter removal, early 
feeding, and multimodal approaches to pain control to minimize opioid use.1-7 Recently, a 
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randomized control trial utilizing a combination of liposomal bupivacaine injected in the 
subcutaneous space with scheduled acetaminophen, and ibuprofen with opioids available for 
breakthrough pain reduced day of surgery opioids by almost 50 percent4, when compared to 
traditional methods of pain control. Our subsequent study also found a 54% reduction in opioids 
along with a 14% reduction in pain scores.5 Liposomal bupivacaine is a lipid encapsulated 
formulation of bupivacaine that extends the therapeutic benefit to several days8 and is indicated 
for injection into the operative site for postsurgical pain.8   
 
West Virginia is a high-risk area with 35.2% obesity9 and is one of the highest drug overdose 
areas in the country at 41.5 per 100,000 and rising.10 Anecdotally, the prevalence of opioid abuse 
and addiction in the area complicates all aspects of postoperative pain control.  This highlights 
the importance of developing new methods of pain control that utilize a multimodal approach to 
reduce the need for potent opioids in this unique population. 
 
Over the past two years, providers at Cabell Huntington Hospital implemented various 
approaches for postoperative pain control.  The implementation and modifications were provider 
driven and implemented equally among each provider’s patients.  Each provider utilized the 
same protocol for all of their patients, instead of choosing different protocols for each patient 
based on preconceived pain tolerance.  Some providers elected to continue with traditional pain 
control methods, while others utilized the traditional postoperative pain control with the addition 
of the On-Q® bupivacaine pump or subcutaneous liposomal bupivacaine.  The On-Q® system 
utilizes percutaneous catheters that infiltrate the abdominal and pelvic cavities with bupivacaine 
over a two to three day period.  Others utilized ERAS orders with the addition of liposomal 
bupivacaine.  
 
Few studies examine the efficacy of multimodal pain control in benign gynecologic cases. Even 
fewer examine this in populations with a high prevalence of addiction.  No existing studies 
analyze the use of the local anesthetics, liposomal bupivacaine or On-Q® while comparing their 
efficacy with traditional postoperative orders and ERAS.   We hypothesized that a specific 
ERAS approach that includes premedication would be superior to traditional control methods in 
controlling postoperative pain and reducing opioid use.  In addition to premedication, the 
hypothesized protocol includes a subcutaneous trocar-site liposomal bupivacaine injection, 
scheduled acetaminophen with tramadol and/or oxycodone as needed for breakthrough pain. We 
compared this approach to five other existing protocols among women undergoing minimally 
invasive hysterectomy.  Our previously reported study was a relatively small study with only 100 
subjects divided into two groups, multimodal and traditional methods.5 This study has 954 
subjects and builds on those findings by adding premedication, evaluation of liposomal 
bupivacaine and On-Q® with traditional pain control methods, and analysis of the potential 
benefit among patients with benign pathology.   
 
Materials and Methods 
 
This is a retrospective cohort study on women undergoing minimally invasive hysterectomy 
categorized into six existing postoperative pain management protocols.  The protocol of interest 
was an enhanced recovery protocol including premedication, subcutaneous liposomal 
bupivacaine, scheduled acetaminophen, and tramadol and/or oxycodone as needed for 
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breakthrough pain (ERAS-1).  The protocols are outlined in Table 1.  ERAS-2 and 3 are similar, 
however they differ from ERAS-1 in that ERAS-2 and 3 do not include premedication.  ERAS-2 
and 3 differ from each other in that ERAS-3 utilizes scheduled tramadol rather than as needed 
tramadol utilized in ERAS-2.  ERAS-3 is the ERAS protocol we previously reported5.  Three 
other protocols were considered traditional.  Traditional pain control methods utilize ibuprofen 
and acetaminophen/oxycodone for breakthrough pain, with IV morphine or hydromorphone for 
severe pain. These protocols all utilized the same postoperative medication and only differed in 
the local that was utilized, liposomal bupivacaine, On-Q® or none.  The group that utilized 
traditional postoperative pain medications without the use of liposomal bupivacaine or On-Q® 
served as the control group (SOC).   
 
Patients were included if they underwent minimally invasive hysterectomy at Cabell Huntington 
Hospital, a tertiary care center, between September 1, 2016 and August 31, 2018 for benign or 
oncologic indications.  This includes both simple and radical hysterectomy with or without 
bilateral salpingo-oophorectomy.  Minimally invasive hysterectomy for the purposes of this 
paper include: robotic-assisted total laparoscopic hysterectomy, total laparoscopic hysterectomy, 
and laparoscopic-assisted vaginal hysterectomy.  Patients were excluded if they had a known 
intraoperative complication, such as gastrointestinal injury or genitourinary injury, or a 
complication that required reoperation within twenty four hours.  Furthermore, patients were 
excluded if an additional abdominal incision was needed for specimen removal.  These 
exclusions were necessary to minimize confounding from pain due to additional incisions, 
prolonged catheterization, or bowel repair.  Patients were also excluded if they were discharged 
on the day of surgery, due to the inability to track postoperative pain and opioid use.  The 
Institutional Review Board approved the study protocol and found it exempt from full review 
based on the low risk to the research subjects.  The authors have no financial disclosures.  We 
have no financial relationship with Pacira Pharmaceuticals, Inc., the manufacturer of Exparel® 
liposomal bupivacaine.  Pacira Pharmaceuticals, Inc. had no role on the study design of this 
project or in the analysis of the data.   
 
Patient medical records were evaluated for the following data points: surgical characteristics, 
demographics, type and dose of opioid administered during hospitalization, and postoperative 
pain scores.  Operative time was defined as the time from incision to skin closure as recorded by 
the circulating nurse.  Pain scores were documented by the floor nurses every 4 hours as part of 
their routine postoperative care using a Likert whole number scale from 0 to 10 with 0 being no 
pain and 10 being severe pain.  Our institution defined adequate pain control as 3 or less.  
Inadequate pain control is considered 5 or more.  All patients received the standard prophylactic 
anti-emetic treatment which was a scopolamine patch.  The need for breakthrough antiemetic for 
nausea and vomiting was also collected.    
 
Preoperative indication was defined as the primary indication for the surgery.  These indications 
were then grouped into indications for oncology, chronic pelvic pain, abnormal uterine bleeding, 
and pelvic organ prolapse.  Oncologic indication was defined as cervical dysplasia or cancer, 
adnexal mass or ovarian cancer, endometrial hyperplasia or cancer, or prophylaxis.   
 
Opioid use recording began once the patient left the operating suite.  Opioids given in the PACU 
was defined as the first postoperative hour, regardless of actual physical location (e.g. recovery 
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room, medical surgical unit).   Opioids given after PACU was defined as opioids given between 
postoperative hours 2 and 24. Total opioids was defined as opioids given in the first 24 hours.  
Standard opioid dose calculators were utilized to convert all opioid class medications to oral 
morphine equivalents.11,12 Conversion from the given opioid to oral morphine used the following 
ratios:  IV morphine 1:3, oxycodone 1:1.5, hydromorphone 1:20, meperidine 1:0.1, hydrocodone 
1:1, fentanyl 1:0.3, and tramadol 0:0.1.  
 
For the purposes of this study, opioids given preoperatively and intraoperatively are not included 
in the dose calculation.  Primary outcomes were morphine total equivalents administered during 
their postoperative course.  Secondary outcomes include median pain scores, nausea and 
vomiting.  For equally distributed data with more than two groups we utilized the analysis of 
variance (ANOVA) or analysis of covariance (ANCOVA).  For non-parametric data with more 
than two groups we utilized the Independent-Kruskal-Wallis tests.  Mann-Whitney U tests was 
used on non-parametric data when there were only two groups.  Fisher Exact test was used on all 
categorical data.  All analyses were performed using SPSS 25. 
 
Results 
  
954 subjects were identified for inclusion within the six protocols described in Table 1. 
Demographics of each groups are shown in Table 2.  Mean age ranged between 44 and 55 years 
with youngest group as control group and oldest as the ERAS-2 group (44 years versus 55 years, 
p<0.001).  Mean BMIs were in the obesity range for each group with the highest in the ERAS-1 
and ERAS-3 groups and the lowest in the control group (36.5 kg/m2 versus 32.1 kg/m2, p 
<0.001).  ERAS groups had less healthy patients with higher incidences of hypertension, 
pulmonary disease and diabetes.  Tobacco use was similar between the groups.  A higher 
proportion of the hysterectomies performed in the ERAS groups were robotic-assisted 
laparoscopic hysterectomies.  ERAS groups had higher proportion of hysterectomies performed 
for oncologic indications whereas the traditional pain control groups had a higher proportion of 
hysterectomies performed for chronic pelvic pain. 
 
As outlined in Table 3 and Figure 1, patients in the ERAS-1 group used the least amount of 
opioids in the PACU at 0.0mg versus 10.0mg in the control group (p=0.004).  After the PACU, 
patients in the ERAS-1 group used 63% less opioids than the control group (13.8mg versus 
37.5mg, p<0.001).  Overall opioid use was the lowest in the ERAS-1 group at 59% less than the 
control at 22.5mg versus 55.0mg, (p<0.001).  Patients in the ERAS-1 group were three times 
more likely, when compared to control, to decline all opioids after the PACU (OR 3.13, CI 1.36-
7.10, p=0.006).  Likewise, patients in the ERAS-1 group were three times more likely, when 
compared to control, to decline all opioids (OR 3.62, CI 1.83-7.18, p<0.001).  When compared to 
control, ERAS-1 patients were five times more likely to use less than 10mg of opioid (OR 4.93, 
CI 2.83-8.59, p<0.001).  A higher proportion of the control group used greater than 50mg and 
100mg at 23% (p<0.001) and 9% (p=0.003) respectively, when compared to the other groups.  
Median pain scores were lowest in the ERAS-2 group at 2.5 and highest in the control group at 
3.5 (p=0.01).  ERAS-1 group, when compared to the control, had a higher proportion of patients 
obtaining a pain score of 3 or less, (64% versus 49%, p=0.01) and 4 or less (87% versus 74%, 
p=0.002).  Conversely, the control group, when compared to the ERAS-1 group, had a higher 
proportion of patients reporting poorly controlled pain with scores of 5 or higher (23% versus 
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10%, p=0.001) and 6 or higher (9% versus 5%, p=0.019).  Patients in the ERAS-1 group reported 
the least nausea at 21% versus 50%, (p<0.001).   
 
For patients undergoing a robotic-assisted hysterectomy, overall opioid use was lowest in the 
ERAS-1 group at 22.5mg versus 58.0mg in the control group (p<0.001).  For patients 
undergoing a TLH or LAVH, overall opioid use was likewise lowest in the ERAS-1 group at 
27.5mg versus 47.5mg in the control (p=0.045).   
 
Outlined in Table 4 and Figure 2, 413 patients had a hysterectomy for an oncologic indication.  
Patients used similar amount of opioids in the PACU, regardless of grouping.  After the PACU, 
patients in the ERAS-1 group used 60% less opioids than the control group (10.0mg versus 
24.8mg, p<0.001).  Overall opioid use was the lowest in the ERAS-2 group at 44% less than the 
control (22.5mg versus 36.0mg, p<0.001).   Patients in the ERAS-1 group had a higher 
proportion of patients who declined all opioids at 11% versus 0% (p=0.006).  Median pain scores 
were similar amongst the groups.   Patients in the ERAS-1 group reported the least nausea at 
17% versus 25% in the control (p<0.001). 
 
Outlined in Table 5 and Figure 3, 318 patients had a hysterectomy for chronic pelvic pain. 
Patients used similar amount of opioids in the PACU, regardless of grouping.  After the PACU, 
patients in the ERAS-1 group used 60% less opioids than the control group (15.0mg versus 
37.5mg, p<0.001).  Overall opioid use was the lowest in the ERAS-1 group at 52% less than the 
control at 26.3mg versus 55.0mg (p<0.001).   Patients in the ERAS-1 group were six times more 
likely, when compared to control, to decline all opioids after the PACU (OR 6.08, 2.16-17.1, 
p<0.001).  Likewise, patients in the ERAS-1 group were six times more likely, when compared 
to control, to decline all opioids (OR 6.06, 1.92-19.07, p=0.02).  When compared to control, 
ERAS-1 patients were ten times more likely to use less than 10mg of opioid (OR 9.74, 4.00-
23.73, p<0.001).  Median pain scores were similar amongst the groups.   Patients in the ERAS-2 
and ERAS-3 groups reported the least nausea at 31% versus 54% in the control and 59% in the 
SOC-OQ (p<0.001). 
 
Discussion 
 
Our data show that the ERAS-1 protocol was associated with a dramatic reduction in the overall 
opioid use and performed the best in our patient population, regardless of preoperative 
indication.  This protocol includes the use of premedication consisting of acetaminophen, 
celecoxib, and pregabalin followed by liposomal bupivacaine with scheduled acetaminophen, 
ibuprofen and simethicone with as needed tramadol for breakthrough pain and oxycodone for 
severe breakthrough pain.  Similar results have been shown with oncologic patients.2-7 This is the 
first study to demonstrate 59% overall reduction in opioid use when compared to control, in a 
population that expects to experience minimal to no pain with surgery and often demands high 
potency opioids.  Furthermore, this study is among the first to evaluate pain control for benign 
conditions as 57 percent of cases were for benign indications. 
  
The use of On-Q® without any changes to postoperative medications did not appear to be 
associated with any reduction in postoperative opioids regardless of the preoperative indication. 
The utilization of subcutaneous liposomal bupivacaine was associated with a 23% reduction in 
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overall opioid use in patients undergoing a hysterectomy for any indication.  However, there was 
no observed difference between those undergoing a hysterectomy for oncologic indications or 
chronic pelvic pain. 
 
ERAS-3, which did not use premedication, was associated with a 9% reduction in overall opioid 
use, which was lower than we previously reported.5  This may be related to a higher n, 190 in our 
current study versus 50 in the previous publication.  There was no observed reduction in overall 
opioid use in patients undergoing a hysterectomy for chronic pelvic pain or oncologic indication.  
We did observe a similar reduction in pain scores as previously reported.5 
 
ERAS-1 and ERAS-2 were very similar in structure with both utilizing liposomal bupivacaine 
with scheduled acetaminophen, ibuprofen and simethicone with as needed tramadol for 
breakthrough pain and oxycodone for severe breakthrough pain.  ERAS-1 added premedication 
consisting of PO acetaminophen, celecoxib, and pregabalin.  Both ERAS-1 and ERAS-2 showed 
significant decreases in overall opioid use of 59 and 55 percent, respectively.  ERAS-1 when 
compared to ERAS-2 was, however, associated with a higher proportion of patients declining all 
opioids after PACU (25% versus 16%, p<0.001), and declining all postoperative opioids (16% 
versus 8%, p<0.001).  ERAS-1 and ERAS-2 performed similar to each other for patients 
undergoing hysterectomy for oncologic indication with both performing better than the control.  
The patients who appear to benefit the most from the premedication are those undergoing a 
hysterectomy for chronic pelvic pain.  We observed a modest decrease of 32% without the 
premedication (ERAS-2), when compared to control.  However, the addition of the 
premedication (ERAS-1) was associated with a 52% reduction in overall opioid use.  ERAS-1, 
when compared to ERAS-2, was associated with a higher proportion of patients declining all 
opioids after PACU (31% versus 14%, p<0.001), and declining all postoperative opioids (25% 
versus 9%, p<0.001).   
 
Our data show that opioid use for postoperative pain can be reduced substantially by using 
premedication, a multimodal approach postoperatively and liposomal bupivacaine. We observed 
relatively small or no differences, when compared to the control, when liposomal bupivacaine or 
the On-Q® were used with traditional postoperative medications.  We observed the largest 
reductions in opioid use amongst the patients in the enhanced recovery groups which utilized 
liposomal bupivacaine exclusively.  This study was not designed to compare On-Q® with 
liposomal bupivacaine.  It is unclear if similar reductions would be identified if the enhanced 
recovery protocols utilized On-Q® instead of liposomal bupivacaine.  Furthermore, it is unclear 
how the enhanced recovery protocols would perform, if no local anesthetic was utilized. 
 
Strengths of our project include that our study also explores a unique population that is obese 
with a high smoking percentage at 32-41%, and lives in an area with a high prevalence of opioid 
use.  Anecdotally, the high prevalence of opioid use complicates postoperative pain management 
as anecdotally we observed that patients expect to experience little to no pain.  This is among the 
larger of the studies examining enhanced recovery in minimally invasive hysterectomy with an n 
of 954.  This is among the first studies to examine pain control in patients who underwent a 
hysterectomy for chronic pelvic pain.  
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Our study has several limitations.  First, as a retrospective study, patients were not randomized to 
any of the groups. Certain providers implemented this protocol in all their patients and others 
exclusively used traditional approaches. This does impose a bias in selection and surgical 
characteristics, which leads to the aberrations observed in the intrinsic validity characteristics.   
Patients in the control group were younger, healthier, more likely to undergo hysterectomy for 
benign indications, and were less likely to undergo a robotic-assisted laparoscopic hysterectomy.  
To account for this potential confounding, ANCOVA was utilized to create corrected models 
shown in Table 6.  These corrected models show similar means when compared to the 
uncorrected model.  Also shown in Table 6, model 7 shows the corrected means for each group, 
when corrected for age, pathology, estimated blood loss, preoperative indication, total operative 
time, comorbidities and type of hysterectomy.  The corrected model shows a statistically 
significant 55% reduction in overall opioid use.  As noted in the results section, patients who 
were in the control group were more likely to undergo a hysterectomy for chronic pelvic pain.  
Model 6 specifically addresses this by adjusting for preoperative indication.  When adjusted for 
preoperative indication, we observed a 57% reduction in opioid use (28.7mg versus 66.3mg, 
p<0.001).   Therefore, despite the differences between the groups, it does not appear that these 
differences significantly altered or cofounded our results.   
 
Second, our population is vastly Caucasian, with insufficient minorities to draw any meaningful 
statistical conclusions regarding minorities.  Therefore, this study is not generalizable to minority 
populations.   
 
Third, patients who underwent surgery earlier in the day would logically have a longer 
postoperative day 0 and thus use more opioids, however this discrepancy would have a limited 
impact as an additional 4 hours of postoperative time would not account for the significant 
differences seen between the groups.  Furthermore, operative start time would be evenly 
distributed between the groups as all providers have their own block time in the morning for their 
cases.   
 
Fourth, our study was not designed to evaluate cost-effectiveness of using liposomal 
bupivacaine.  Despite the higher initial cost of liposomal bupivacaine compared to no local 
anesthetic,6,7 pharmacy costs have been shown to be overall equivocal6 and overall hospital costs 
reduced by ten percent.7 
  
Fifth, a patient’s personal history of drug use was not included as this information is often 
inconsistent and unreliable.  Urine drug screens are not routinely collected preoperatively, 
therefore this information was not included.  Therefore, our data may not be reproducible in 
patients with a known history of substance dependence.  This would be a potential area for future 
research. 
 
In conclusion, ERAS-1 is an acceptable alternative to traditional methods of pain control, 
regardless of preoperative indication.  This protocol was associated with the highest opioid use 
reduction at 59%.   Patients with chronic pelvic pain appeared to benefit the most and those who 
received this protocol were six times more likely to decline all opioids and ten times more likely 
to use less than 10mg of opioid.  This study shows the promise of multimodal protocols in 
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reducing opioid need postoperatively.  Further prospective randomized control trials are 
warranted. 
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Table 1.  Groups Included for Analysis 
Group Preoperative Intraoperative 
Local 
Postoperative 
ERAS-1 
n=110 
1g PO acetaminophen 
200mg PO celecoxib 
75mg PO pregabalin 
 
Routine anti-emetic 
prophylaxis 
266mg (20mL) 
subcutaneous 
liposomal 
bupivacaine  
• 500mg PO acetaminophen q4 hours scheduled 
• 800mg PO ibuprofen q8 hours scheduled 
• 50mg PO tramadol q4 hours as needed for 
breakthrough pain 
• 5mg PO oxycodone q6 hours as needed for 
severe breakthrough pain 
• 80mg PO simethicone three times daily 
• Abdominal binder 
 
ERAS-2 
N=84 
Routine anti-emetic 
prophylaxis 
266mg (20mL) 
subcutaneous 
liposomal 
bupivacaine 
• 500mg PO acetaminophen q4 hours scheduled 
• 800mg PO ibuprofen q8 hours scheduled 
• 50mg PO tramadol q4 hours as needed for 
breakthrough pain 
• 5mg PO oxycodone q6 hours as needed for 
severe breakthrough pain 
• 80mg PO simethicone three times daily 
• Abdominal binder 
 
ERAS-3 
n=190 
Routine anti-emetic 
prophylaxis 
266mg (20mL) 
subcutaneous 
liposomal 
bupivacaine 
• 500mg PO acetaminophen q4 hours scheduled 
• 800mg PO ibuprofen q8 hours scheduled 
• 50mg PO tramadol q4 hours scheduled 
• 5mg PO oxycodone q6 hours as needed for 
severe breakthrough pain 
• 80mg PO simethicone three times daily 
• Abdominal binder 
 
SOC-LB 
n=140 
Routine anti-emetic 
prophylaxis 
266mg (20mL) 
subcutaneous 
liposomal 
bupivacaine 
• 325/5 acetaminophen/oxycodone q4 hours as 
needed for mild pain 
• 325/10 acetaminophen/oxycodone q4 hours as 
needed for severe pain 
• IV Morphine or hydromorphone for severe 
pain 
• 800mg PO ibuprofen every 8 hours scheduled 
SOC-OQ 
n=249 
Routine anti-emetic 
prophylaxis 
On-Q® • 325/5 acetaminophen/oxycodone q4 hours as 
needed for mild pain 
• 325/10 acetaminophen/oxycodone q4 hours as 
needed for severe pain 
• IV Morphine or hydromorphone for severe 
pain 
• 800mg PO ibuprofen every 8 hours scheduled 
SOC 
(Control) 
n=181 
Routine anti-emetic 
prophylaxis 
None • 325/5 acetaminophen/oxycodone q4 hours as 
needed for mild pain 
• 325/10 acetaminophen/oxycodone q4 hours as 
needed for severe pain 
• IV Morphine or hydromorphone for severe 
pain 
• 800mg PO ibuprofen every 8 hours scheduled 
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Table 2.  Demographics by Group (n=954) 
Characteristic  ERAS-1 (n=110)  ERAS-2 (n=84)  ERAS-3 (n=190) SOC-LB (n=140) SOC-OQ (n=249) Control (n=181)  p 
Age (years)  51 (49 - 54) 55 (52 - 58) 54 (52-55) 53 (51 - 55) 46 (45 - 48) 44 (43-45)  <0.001‡  
BMI (kg/m2)  36.4 (34.5-38.4) 34.5 (32.6-36.4) 36.4 (34.9-38.0) 32.9 (31.4-34.4) 32.6 (31.5-33.7) 32.1 (33.1-33.2)   <0.001‡ 
 
Medical Characteristics 
 Hypertension 51 (46)  38 (45)  106 (56)  71 (51)  82 (33)  65 (36)   <0.001§ 
 Pulmonary Disease             <0.001§ 
  Asthma 15 (14)  6 (7)  17 (9)  17 (12)  38 (15)  22 (12) 
  COPD 17 (16)  2 (2)  11 (6)  13 (9)  10 (4)  4 (2) 
 Diabetes               <0.001§ 
  Type 1 0 (0)  1 (1)  2 (1)  1 (1)  2 (1)  0 (0) 
  Type 2 28 (26)  14 (17)  49 (26)  27 (19)  27 (11)  12 (7) 
Tobacco               0.415§ 
  Former 18 (16)  15 (18)  34 (18)  20 (14)  42 (17)  20 (11)    
  Current 27 (25)  12 (14)  38 (20)  37 (26)  62 (25)  47 (26)  
 
Surgical Characteristics 
 Duration (min) 69 (62-76) 76 (69-83) 69 (64-74) 74 (68-80) 120 (114-125) 126(119-133)  <0.001§ 
 EBL (mL) 58 (52-65) 49 (40-58) 52 (46-57) 58 (51-66) 79 (72-85) 92 (80-103)  <0.001§ 
 Adhesion lysis 19 (17)  19 (23)  28 (15)  19 (14)  54 (22)  16 (181)   0.182§ 
  
Type                <0.001§ 
 TLH  4 (4)  0 (0)  1 (1)  0 (0)  18 (7)  20 (11)  
 RaTLH  97 (88)  77 (92)  187 (98)  130 (93)  205 (82)  114 (63) 
 LAVH  9 (8)  8 (8)  2 (1)  10 (7)  26 (10)  47 (26) 
 
Preoperative Indication              <0.001§ 
    Oncologic  66 (60)  52 (61)  128 (67)  89 (64)  62 (25)  16 (8)    
    Chronic pelvic pain 32 (29)  22 (26)  31 (16)  36 (26)  145 (58)  115 (64) 
    Abnormal bleeding 10 (9)  8 (10)  29 (15)  13 (9)  37 (15)  31 (17) 
    Pelvic organ prolapse 2 (2)  2 (2)  2 (1)  2 (1)  5 (2)  19 (11) 
Final Path Malignant 37 (34)  26 (31)  72 (38)  52 (37)  26 (10)  0 (0)   <0.001§ 
 
data are mean (95% Confidence Interval) or n (percent) 
‡ANOVA 
§Fisher-Exact 
TLH – Total Laparoscopic Hysterectomy with or without oophorectomy 
RaTLH – Robotic Assisted Total Laparoscopic Hysterectomy with or without oophorectomy 
LAVH – Laparoscopic Assisted Vaginal hysterectomy with or without oophorectomy 
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Table 3.  Primary Outcomes Group (n=954) 
Characteristic  ERAS-1 (n=110)  ERAS-2 (n=84)  ERAS-3 (n=190) SOC-LB (n=140) SOC-OQ (n=249) Control (n=181)  p 
Opioid use (mg PO Morphine) 
 PACU  0.0 (0.0– 15.0) 8.0 (0.0 -23.0) 15.0 (0 - 30) 15.0 (0 - 23) 8.0 (0 - 23) 10.0 (0 - 25)  0.004‡  
 (% change, p)* -100 (0.420) -20 (0.876) +50 (0.015) +50 (0.133) -20 (0.889) 
After PACU 13.8 (4.4-23.1) 15.0 (5.0-25.0) 35.0 (25.0-45.0) 28.0 (14.4-42.6) 37.5 (9.1-65.9) 37.5 (10.0-65.0)  <0.001‡ 
(% change, p)* -63 (<0.001) -60 (<0.001) -7 (<0.001) -25 (<0.001) 0 (0.960)   
Total  22.5 (4.7-40.3) 25.0 (5.0-45.0) 50.0 (30.0-70.0) 42.5 (22.0-63.0) 51.0 (22.3-79.8) 55.0 (21.1-88.9)   <0.001‡ 
(% change, p)* -59 (<0.001) -55 (<0.001) -9 (0.025) -23 (0.001) -7 (0.928) 
 
Zero opioid after PACU 27 (25)  13 (16)  0 (0)  12 (9)  24 (10)  15 (8)   <0.001§ 
 
Zero opioid use  17 (16)  7 (8)  0 (0)  6 (4)  16 (6)  10 (6)   <0.001§  
 
Opioid use <10mg 51 (46)  38 (45)  8 (4)  31 (22)  46 (19)  27 (15)   <0.001§ 
 
Opioid use >50mg 
   3 (3)  3 (4)  14 (7)  11 (8)  44 (18)  42 (23)   <0.001§ 
 
Opioid use >100mg 
  0 (0)  1 (1)  1 (1)  2 (1)  14 (6)  16 (9)   0.003§ 
Pain 
Median Pain Scores 3.0 (2.0-4.0) 2.5 (1.0-4.0) 3.0 (2.0-4.0) 3.0 (2.0-4.0) 3.0 (2.0-4.0)  3.5 (2.4-4.6)  0.010‡ 
  
 3 or less  70 (64)  60 (71)  112 (59)  87 (62)  138 (55)  89 (49)   0.010§ 
 4 or less  96 (87)  78 (93)  157 (83)  115 (82)  193 (78)  134 (74)   0.002§ 
 5 or more 11 (10)  5 (6)  26 (14)  23 (16)  52 (21)  42 (23)   0.001§ 
 6 or more  5 (5)  1 (1)  7 (4)  7 (5)  23 (9)  17 (9)   0.019§ 
 7 or more 2 (2)  1 (1)  2 (1)  1 (1)  9 (4)  5 (3)   0.318§ 
 
Nausea   23 (21)  20 (24)  52 (27)  34 (25)  132 (53)  91 (50)   <0.001§ 
data are median (interquartile range) or n (percent) 
‡Independent-Kruskal-Wallis Test 
§Fisher-Exact 
*percent change compared to control (Mann-Whitney U test)  
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 Table 4.  Primary Outcomes by Group Oncologic Indication (n=413) 
Oncological Indication includes: endometrial hyperplasia/malignancy, cervical dysplasia/malignancy, adnexal mass/malignancy, prophylaxis 
Characteristic  ERAS-1 (n=66)  ERAS-2 (n=52)  ERAS-3 (n=128) SOC-LB (n=89) SOC-OQ (n=62) Control (n=16)  p 
Opioid use (mg PO Morphine) 
 PACU  0.0 (0 – 15.0) 6.0 (0.0 -21.0) 20.0 (5.0-35.0) 15.0 (0 – 30.0) 8.0 (0 – 3.0) 3.0 (0 – 18.0)  0.107‡  
 (% change, p)* -100 (0.890) +100 (0.975) +567 (0.225) +400 (0.313) +167 (0.861) 
After PACU 10.0 (1.3-18.8) 15.0 (5.0-25.0) 35.0 (27.8-42.2) 26.0 (12.9-39.1) 30.8 (10.4-51.1) 24.8 (0-56.9)  <0.001‡ 
(% change, p)* -60 (0.015) -40 (0.025) +41 (0.539) +5 (0.206) +24 (0.741)   
Total  22.5 (8.3-36.8) 20.0 (0-40.0) 50.0 (31.3-68.8) 42.0 (22.1-61.9) 37.5 (0-76.3) 36.0 (0.00-74.3)   <0.001‡ 
(% change, p)* -38 (0.033) -44 (0.061) +39 (0.955) +17 (0.490) +4 (0.849) 
 
Zero opioid after PACU 15 (23)  10 (19)  0 (0)  9 (10)  10 (16)  1 (6)   <0.001§ 
 
Zero opioid use  7 (11)  5 (10)  0 (0)  5 (6)  7 (11)  0 (0)   0.006§  
 
Opioid use <10mg 34 (52)  24 (47)  5 (4)  22 (25)  15 (24)  4 (25)   <0.001§ 
 
Opioid use >50mg 
   0 (0)  2 (4)  7 (6)  7 (8)  12 (19)  3 (19)   <0.001§ 
 
Opioid use >100mg 
  0 (0)  1 (2)  0 (0)  2 (2)  1 (2)  1 (6)   0.230§ 
Pain 
Median Pain Scores 3.0 (1.7-4.3) 2.0 (1.0-3.0) 3.0 (2.0-4.0) 3.0 (2.0-4.0) 3.0 (1.8-4.3)  3.0 (1.8-4.3)  0.113‡ 
 
 3 or less  42 (64)  41 (79)  73 (57)  61 (69)  40 (65)  9 (56)   0.113§ 
 4 or less  61 (92)  51 (100)  103 (81)  77 (87)  50 (81)  15 (94)   0.005§ 
 5 or more 4 (6)  0 (0)  20 (16)  12 (14)  11 (18)  1 (6)   0.017§ 
 6 or more  2 (3)  0 (0)  6 (5)  3 (3)  4 (7)  0 (0)   0.485§ 
 7 or more 1 (2)  0 (0)  2 (2)  0 (0)  3 (5)  0 (0)   0.200§ 
 
Nausea   11 (17)  11 (21)  33 (26)  19 (21)  32 (52)  4 (25)   <0.001§ 
data are median (interquartile range) or n (percent) 
‡Independent-Kruskal-Wallis Test 
§Fisher-Exact  
*percent change compared to control (Mann-Whitney U test)  
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Table 5.  Primary Outcomes by Group Chronic Pelvic Pain (n=381) 
Characteristic  ERAS-1 (n=32)  ERAS-2 (n=22)  ERAS-3 (n=31) SOC-LB (n=36) SOC-OQ (n=145) Control (n=115)  p 
Opioid use (mg PO Morphine) 
 PACU  0.0 (0.0 – 15.0) 12.5 (0.0 -27.5) 20.0 (0.0-40.0) 15.0 (0.0 – 30.0) 6.0 (0.0 – 21.0) 12.0 (0.0 – 27.0)  0.178‡  
 (% change, p)* -100 (0.454) +4 (0.968) +67 (0.153) +25 (0.630) -50 (0.349) 
After PACU 15.0 (0-31.3) 22.5 (7.2-37.8) 35.0 (25.0-45.0) 32.5 (15.0-50.0)) 43.5 (17.3-69.8) 37.5 (11.3-63.8)  <0.001‡ 
(% change, p)* -60 (<0.001) -40 (0.003) -7 (0.055) -13 (0.065) +16 (0.233)   
Total  26.3 (4.4-48.1) 37.3 (5.4-49.2) 55.0 (39.3-70.8) 59.3 (37.3-81.4) 59.0 (31.3-86.8) 55.0 (19.8-90.3)   0.001‡ 
(% change, p)* -52 (<0.001) -32 (0.001) 0 (0.568) +8 (0.213) +7 (0.432) 
 
Zero opioid after PACU 10 (31)  3 (14)  0 (0)  2 (6)  11 (8)  9 (8)   0.001§ 
 
Zero opioid use  8 (25)  2 (9)  0 (0)  0 (0)  8 (6)  6 (5)   <0.001§  
 
Opioid use <10mg 19 (59)  14 (64)  1 (3)  5 (14)  22 (15)  15 (13)   <0.001§ 
 
Opioid use >50mg 
   3 (9)  1 (5)  5 (16)  4 (11)  27 (19)  68 (18)   0.119§ 
 
Opioid use >100mg 
  0 (0)  0 (0)  1 (3)  0 (0)  11 (8)  10 (9)   0.128§ 
Pain 
Median Pain Scores 3.0 (1.8-4.2) 3.00 (1.6-4.4) 3.0 (2.0-4.0) 3.5 (2.6-4.5) 3.0 (1.8-4.3)  3.0 (2.3-3.8)  0.839‡ 
 
 3 or less  20 (63)  9 (41)  15 (48)  18 (50)  71 (49)  57 (50)   0.839§ 
 4 or less  24 (75)  17 (77)  26 (84)  27 (75)  108 (75)  87 (76)   0.936§ 
 5 or more 6 (19)  4 (18)  3 (10)  8 (22)  35 (24)  27 (24)   0.597§ 
 6 or more  3 (9)  1 (5)  0 (0)  4 (11)  17 (12)  12 (10)   0.435§ 
 7 or more 1 (3)  1 (5)  0 (0)  1 (3)  5 (3)  2 (2)   0.859§ 
 
Nausea   11 (34)  7 (32)  10 (32)  11 (31)  85 (59)  62 (54)   0.001§   
data are median (interquartile range) or n (percent) 
‡Independent-Kruskal-Wallis Test 
§Fisher-Exact  
*percent change compared to control (Mann-Whitney U test)  
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Table 6.  Unadjusted and Adjusted Total Opioid Mean (mg PO Morphine) By Group (n=954) 
Model   ERAS-1  ERAS-2  ERAS-3  SOC-LB SOC-OQ  Control    p  
Model 1  28.8 (20.4-37.2) 32.5 (22.8-42.1) 56.4 (50.0-62.8) 49.2 (41.8-56.7) 65.9 (60.3-71.5) 66.4 (59.8-72.9)  <0.001* 
Model 2  30.2 (22.0-38.4) 36.6 (27.1-46.1) 59.4 (53.1-65.7) 51.9 (44.6-59.2) 63.2 (57.7-68.8) 62.0 (55.5-68.5)  <0.001* 
Model 3  28.1 (19.5-36.7) 32.0 (22.2-41.7) 55.7 (49.0-62.3) 48.7 (41.1-56.3) 66.6 (60.7-72.4) 67.2 (60.3-74.2)  <0.001* 
Model 4  28.4 (19.9-36.8) 32.4 (22.7-42.0) 55.9 (49.5-62.4) 49.4 (41.9-56.9) 66.1 (60.5-71.7) 66.7 (60.1-73.3)  <0.001* 
Model 5  28.4 (19.9-36.8) 33.0 (23.4-42.7) 57.4 (50.9-63.9) 49.5 (42.1-57.0) 65.2 (59.5-70.8) 66.1 (59.5-72.7)  <0.001* 
Model 6  28.7 (20.3-37.2) 32.4 (22.8-42.1) 56.4 (50.0-62.8) 49.1 (41.6-56.6) 66.1 (60.5-71.7) 66.3 (59.7-72.9)  <0.001* 
Model 7  28.9 (20.4-37.3) 35.6 (26.0-45.2) 57.9 (51.3-64.5) 41.1 (43.7-58.6) 64.4 (58.7-70.2) 63.7 (56.8-70.7)  <0.001* 
Data are mean, (95% CI) 
*ANCOVA 
Model 1: Unadjusted 
Model 2: Adjusted for Age 
Model 3: Adjusted for Operative Time 
Model 4: Adjusted for BMI 
Model 5: Adjusted for Comorbidities (Hypertension, Pulmonary Disease, and Diabetes) 
Model 6: Adjusted for Preoperative Indication (Oncologic, Abnormal Uterine Bleeding, Chronic Pelvic Pain, Pelvic Organ Prolapse) 
Model 7: Adjusted for age, pathology (malignancy vs. benign), estimated blood loss, total operative time, comorbidities, preoperative indication, and type of 
hysterectomy (RaTLH, TLH, LAVH) 
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Figure 1.  Median Opioid Use by Protocol.  Median opioid use by group patients who underwent a hysterectomy for 
any indication (n=954) in mg PO Morphine.  
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Figure 2.  Median Opioid Use by Protocol by those with Oncologic Indication.  Median opioid use by group in 
patients who underwent a hysterectomy for oncologic indication (n=413) in mg PO Morphine.   
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Figure 3.  Median Opioid Use by Protocol by those with Chronic Pelvic Pain.  Median opioid use by group in 
patients who underwent a hysterectomy for oncologic indication (n=381) in mg PO Morphine.   
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